Rodller has a wide scale of Mandates to Source Investment Deals for its Venture Capital Partners. But one mandate was not yet fully addressed. Biotech. This industry is tricky and requires deep knowledge to assess the credibility of each opportunity. We Partnered with a VC specialist that can assist us in Sourcing valid deals, garantueeing continuous quality for our VC Customers, that do have the Biotech in their Mandate. The global venture capital investments in biotechnology have grown substantially over the past decade. The value of venture capital funding was $26.29 billion in 2019, which was a nearly four-fold increase from $6.6 billion in 2010. The biotechnology sector attracted most of the investment within the healthcare sector, followed by medical devices, digital health, and healthcare services. These investments have been increasing year over year, with biomedical and IT/healthcare leading the way. The most prominent VC investors in biotechnology have been large venture capital firms such as Kleiner Perkins, Andreessen Horowitz, BioVentures, New Enterprise Associates, Arch Venture Partners, Versant Ventures, and Abingworth. Other venture capital investors active in biotechnology include Sofinnova, Venrock, Google Ventures, and OrbiMed. U.S. based venture capital firms have been the most active investors in biotech ventures, particularly in the preclinical and clinical-stage categories, pouring a total of $17.3 billion into biotech companies from 2010 to 2019. However, interest from European and Asian investors is also growing, and venture capital firms located in these regions have made investments in biotechnology totaling nearly $4 billion in this same period. Rodller is proud to have a say in this space.